Fecal immunochemical tests (FITs) for hemoglobin are increasingly recommended and used in colorectal cancer (CRC) screening. We aimed to provide a detailed assessment of the sensitivity of FIT according to type and subsite of neoplasms in a true screening setting. A quantitative FIT (FOB Gold, Sentinel Diagnostics, Milano, Italy) was applied prior to colonoscopy by 3,466 participants of the German screening colonoscopy program. Subsite specific sensitivity for various types of colorectal neoplasms was derived by comparing FIT results with findings at screening colonoscopy. The most advanced finding at colonoscopy was CRC, advanced adenoma, and nonadvanced adenoma in 29, 354 and 686 cases, respectively. Per-adenoma sensitivity for large advanced adenomas (>1 cm) strongly varied by location (p < 0.001): cecum: 0/14 (0%), ascending colon and right flexure: 11/43 (26%), transverse colon and left flexure: 2/14 (14%), descending colon: 7/12 (58%), sigmoid colon: 47/92 (51%), rectum: 14/39 (36%). By contrast, the FIT detected all of 5 proximal CRC and 23 out of 24 (96%) distal CRCs, whereas per-adenoma sensitivity of both proximal (17/259, 7%) and distal nonadvanced adenomas (20/237, 8%) essentially equaled the false positivity rate among those without neoplasms (152/2,397, 6%). In conclusion, we found a very large gradient of subsite specific FIT sensitivity for detecting large advanced adenomas ranging from 0% for advanced adenomas located in the cecum to >50% for those located in the descending or sigmoid colon. By contrast, FIT sensitivity was uniformly excellent for CRC and uniformly poor for nonadvanced adenomas, regardless of their location.
Fecal immunochemical tests (FITs) for hemoglobin are increasingly recommended and used in colorectal cancer (CRC) screening. 1 They have several advantages over traditional guaiac based fecal occult blood tests, including higher sensitivity, more convenient sample handling, and higher adherence rates, and they do not require dietary restrictions. [2] [3] [4] A crucial parameter determining the relative merit of the use of FITs compared to alternative screening tests, such as flexible sigmoidoscopy (FS) , is to what extent FITs can detect proximal neoplasms in the same way as distal neoplasms.
A number of studies have addressed site specific sensitivity of FITs, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and most of them found somewhat lower sensitivity for proximal compared to distal neoplasms. [5] [6] [7] [8] [9] [10] [12] [13] [14] Typically, however, no further distinction according to subsite within the proximal colon or distal colon and rectum was made. Also, results were rather heterogeneous, as were the definitions of site and types of neoplasms and of the subgroups of patients for which site specific sensitivity was determined: In some studies, sensitivity for detecting proximal neoplasms was determined irrespective of the presence of distal neoplasms (or vice versa). 14 This approach reflects the proportion of carriers of proximal neoplasms that would be expected to have a positive FIT result in practice, even though some of the positive FIT results may be due to bleeding of a distal neoplasm. We therefore will denote the sensitivity determined this way "apparent sensitivity." Other studies have determined sensitivity among participants who exclusively had proximal or distal neoplasms. 5, 9 With this approach positive results for proximal neoplasms cannot result from bleeding of distal neoplasms and vice versa. We therefore denote the site specific sensitivity determined this way "true sensitivity." An even more specific approach is to determine "per-neoplasm" sensitivity, such as "per-adenoma" sensitivity among participants with one adenoma only. Here, we empirically assess and compare the different measures of site specific sensitivity for different types of neoplasms in a large cohort of participants of screening colonoscopy from Germany.
Methods

Study design and study population
Our analysis is based on data from the ongoing German BLITZ study whose design has been described in detail previously. 3, [15] [16] [17] The study has been approved by the Ethics Com- In the BLITZ study, different FITs were evaluated at various periods. The current analysis focuses on participants recruited at ages 50-79 years from November 2008 to September 2014 when the same quantitative FIT (FOB Gold, Sentinel Diagnostics, Milano, Italy) was applied (N 5 4,162). A number of exclusion criteria were applied to ensure the samples to be representative of an average-risk screening population and to minimize the number of screening colonoscopies with missed neoplasms: (i) history of CRC or inflammatory bowel disease (N 5 32); (ii) colonoscopy in the preceding 5 years (N 5 188); (iii) inadequate bowel preparation before colonoscopy (N 5 426); (iv) incomplete colonoscopy (cecum not reached) (N 5 50). After these exclusions 3,466 participants were retained for the analysis.
Data and sample collection
Patients were recruited, and informed consent was obtained at a pre-colonoscopy visit in the practice. Participants were asked to fill a self-administered questionnaire on factors potentially related to CRC risk, and they were handed out devices for stool collection. There were no specific dietary or medication restrictions before fecal sampling. During the recruitment period, two different fecal sampling methods were employed. Until January 2012, participants were asked to fill small containers or stool collection tubes (Sarstedt; Ref 80.623.022) with raw native fresh stool samples, store them in provided plastic bags, keep them in the freezer and bring them to the practice visit for colonoscopy. At the practice visit, the stool-filled containers were immediately stored in the freezer (215 to 2408C) again, and shipped on dry ice to a central laboratory within one to few days, where they were stored at 2708C until analysis. From February 2012 on, participants were asked to collect stool samples according to routine clinical practice, that is, in stool collection tubes containing hemoglobin stabilizing buffers (10 mg stool in 1.7 ml extraction buffer, Sentinel Diagnostics, Milano, Italy; Ref. 11561H). The tubes were to be sealed in envelopes, which were then mailed to the study center at the German Cancer Research Center, where they were kept at 2 to 88C in the refrigerator before transporting in a cold chain to the central, DIN EN ISO 15189 accredited laboratory (Labor Limbach, Heidelberg, Germany) for FIT analysis.
All collection, arrival and analysis dates of fecal samples were documented. For frozen stool samples, the median time [interquartile range (IQR)] between fecal sampling and laboratory analysis was 6 (IQR 5 4 2 12) days; for fresh stool samples, the median time (IQR) between fecal sampling and arrival in DKFZ was 4 (IQR 5 3 2 5) days, and the median time between arrival at DKFZ and laboratory analysis was 2 (IQR 5 1 2 4) days.
Clinical data were extracted from colonoscopy and histology reports. The data extraction was done in a standardized manner by trained research assistants who were blinded with respect to questionnaire data and results of stool tests.
Laboratory analyses
FIT reporting and evaluation followed FITTER standards. 19 FOB Gold (Sentinel Diagnostics, Milano, Italy) which is based on a latex agglutination assay was used for measuring fecal hemoglobin concentrations. Laboratory personnel was fully blinded with respect to questionnaire data and colonoscopy findings. Raw frozen stool samples were thawed once, and an automatic stool extraction system was used to extract 10 mg stool, which was then diluted in the extraction buffer What's new? Fecal immunochemical tests for hemoglobin are increasingly used in colorectal cancer (CRC) screening, but detailed diagnostic performance characteristics according to the type and location of neoplasms are still lacking. Here, the authors aimed to provide a detailed sensitivity assessment in a true screening setting. Among 3,466 participants to the German screening colonoscopy program, the authors found that sensitivity was close to 100% for CRC and 0% for non-advanced adenomas at any location. In contrast, site-specific sensitivity for large advanced adenomas varied from 0% (cecum) to >50% (distal colon). The results provide an important empirical basis for further enhancing CRC screening.
(1.7 ml, i.e., dilution: 1:170) as in stool collection according to routine clinical practice. All FIT analyses were conducted in a fully automated manner using Abbott Architect c8000. Positivity was defined according to the cutoff recommended by the manufacturer (17 mg hb/g feces ‫-‬ 100 ng hb/ml buffer). The dates of conducting FIT analyses were recorded.
Statistical analyses
FIT results and diagnostic performance indicators were very similar for both stool sampling methods, and therefore all results were pooled for the analyses. We first described the study population according to sex, age and prevalences of the most advanced findings at screening colonoscopy, overall and according to their location in the proximal colon (proximal of or at splenic flexure) only, in the distal colon or rectum only, or in both parts of the colon and rectum. Screening colonoscopy was used as reference test in all analyses which, though not being perfect, is considered the gold standard for detecting colorectal neoplasms. Colonoscopists were blind with respect to FIT results. The most advanced findings at screening colonoscopy were categorized as follows: (i) CRC (any stage or Stages I-III only), (ii) advanced adenomas (defined by at least one adenoma with any of the following features: 1 cm in size, tubulovillous or villous components, high grade dysplasia, (iii) nonadvanced adenoma, (iv) no neoplasm.
We then determined the sensitivity for detecting the various types of neoplasms according to their location. These analyses were conducted in two alternative ways: analyses of "apparent sensitivities" for proximal neoplasms included all participants with the most advanced type of neoplasm being located in the proximal colon, regardless if such a neoplasm was also found in the distal colon and rectum. Similarly, analyses of apparent sensitivities for distal neoplasms included all participants with the most advanced type of neoplasm being located in the distal colon or rectum, regardless if such a neoplasm was also found in the proximal colon. By contrast, analyses of "true sensitivities" for proximal neoplasms and of true sensitivities for distal neoplasms included only participants with the most advanced type of neoplasms exclusively located in the proximal colon or in the distal colon and rectum, respectively. We did though not exclude participants from site specific analyses of true sensitivities for the most advanced neoplasms if less advanced neoplasms were found in the complementary site, assuming that the most advanced finding would be the most likely source of potential bleeding. This assumption, which also was made in determination of site specific sensitivity in a number of previous studies 6, 8, 12, 13 seems justified given the very strong gradient of FIT sensitivities according to the most advanced finding at colonoscopy. 3 In addition to true sensitivities for the most advanced neoplasms exclusively located in the proximal colon or in the distal colon and rectum, we also determined sensitivities for simultaneous occurrence of the most advanced type of neoplasms on both parts of the colon and rectum.
Sensitivities were also derived according to combinations of the aforementioned groups, such as participants with any advanced neoplasm, that is, CRC or advanced adenoma, or participants with any neoplasm, that is, CRC or any adenoma.
In addition to the aforementioned apparent and true "perparticipant" sensitivities, which refer to participants with either single or multiple neoplasms of the respective most advanced type, we also calculated "per-adenoma" sensitivities among participants with a single advanced adenoma ("peradvanced-adenoma sensitivity") or a single nonadvanced adenoma ("per-nonadvanced-adenoma sensitivity") only. In the calculation of the per-advanced-adenoma sensitivities we also included participants who had one or more nonadvanced adenomas besides the advanced adenoma, again assuming that the advanced adenoma would be the most likely source of potential bleeding. Analyses of per-advanced-adenoma sensitivities were also carried out for advanced neoplasms located in specific subsites of the proximal colon (cecum, ascending colon, right flexure/transverse colon), or the distal colon and rectum (left flexure/descending colon, sigmoid colon, rectum).
Fisher's exact test was applied to examine statistical differences of site specific sensitivities. All tests were two-sided, and p-values of 0.05 or less were considered to be statistically significant. Statistical analyses were performed with statistical software R version 3.1.1. 20 
Results
Main characteristics of the study population are shown in Table 1 . The study included almost equal numbers of men and women. Slightly less than half of the participants were below 60 years of age, with age group 55-59 being the by far largest age group. The most advanced finding at colonoscopy was CRC, advanced adenoma and nonadvanced adenoma in 0.8, 10.2 and 19.8% of participants, respectively. These proportions were substantially higher in men than in women. Table 2 shows the numbers and site distribution of the most advanced neoplasms. Whereas the vast majority of CRCs (24 of 29, 83%) were located in the distal colon and rectum, with no co-occurrence at both sites, the site distribution was more balanced for adenomas, even though a clear majority of advanced adenomas was also located in the distal colon and rectum. Nonadvanced adenomas as the most advanced finding were slightly more common in the proximal colon. Among 354 cases with advanced adenoma as the most advanced finding, 21 (5.9%) had both a proximal and a distal advanced adenoma. Among 686 cases with nonadvanced adenoma as the most advanced finding, 76 (11.1%) had both a proximal and a distal nonadvanced adenoma. Table 3 shows apparent site specific sensitivity of detecting proximal and distal neoplasms, ignoring co-occurrence of neoplasms at both sites. Of the 29 CRCs, all but one were detected by the FIT, resulting in site specific sensitivities of 100% (proximal colon) and 96% (distal colon and rectum). Apparent sensitivity for advanced adenoma, in particular 3 Site information missing in 4 cases. 4 Site information missing in 1 case. 5 Site information missing in 1 case. 6 Site information missing in 5 cases. large advanced adenoma (1 cm) was substantially higher for distal (51%) than for proximal (24%) location. Much lower apparent sensitivities (10%) were seen for nonadvanced adenoma regardless of location. These sensitivities hardly exceeded the positivity rates of 6% among the 2,397 participants in whom no neoplasms were detected at screening colonoscopy (data not included in Table) . The already relatively low apparent sensitivity for proximal advanced adenoma (20%) was further substantially reduced to 14% when participants with advanced adenoma in the proximal colon only were considered ("true sensitivity," Table 4 ). By contrast, sensitivity for distal advanced adenoma was almost the same whether (44%) or not (43%) additional advanced adenoma was present in the proximal colon. Sensitivity was highest in case of co-occurrence of advanced adenoma in both the proximal colon and the distal colon and rectum (52%). The difference in true sensitivity for proximal advanced adenoma (14%) and distal advanced adenoma (43%) was highly statistically significant at p < 0.001. The same applies to site comparisons of true sensitivities focusing on large advanced adenomas only, or on combined endpoints of CRC with advanced adenomas.
Per-adenoma sensitivities determined among those with only one advanced adenoma or only one nonadvanced adenoma were slightly lower than the per-participant sensitivities (Table 5 ). In particular, per-adenoma sensitivity of both proximal and distal nonadvanced adenomas (7 and 8%, respectively), was essentially as low as the false positive rate among those with no neoplasm (6%), indicating that the FIT did not detect these adenomas. However, per-adenoma sensitivity was still as high as 40% and 48% for any and large ( 1 cm) distal advanced adenomas, respectively.
As Table 6 shows, per-advanced adenoma sensitivity was no better than the false positivity rate even for advanced adenomas when they were located in the cecum (5%). Peradenoma sensitivity was still rather poor at levels between 11 and 21% for advanced adenomas located between the ascending colon and the left flexure, but increased to 44% for advanced adenomas located in the descending or sigmoid colon; slightly lower sensitivities (33%) were observed for advanced adenomas located in the rectum. An even more pronounced gradient was seen for "per-large-advancedadenoma sensitivities," which ranged from 0% for large adenomas in the cecum to levels above 50% for large advanced adenomas in the descending or sigmoid colon. Despite low numbers of advanced adenomas in some of the subsites, the differences in sensitivity for detecting any or large advanced adenomas were highly statistically significant (p < 0.001).
Discussion
In this large population of participants of screening colonoscopy, a quantitative FIT detected all but one of 29 CRCs. Sensitivity for detecting advanced adenomas strongly varied by location. Sensitivity for detecting proximal advanced adenomas was substantially lower (20%) than sensitivity for detecting distal advanced adenoma (44%) even when cooccurrence of advanced adenoma at the complementary site was neglected ("apparent sensitivity"). Sensitivity for detecting proximal advanced adenomas dropped to 14% when focusing on participants with advanced adenoma in the proximal colon only ("true sensitivity"), whereas sensitivity for detecting advanced adenomas remained almost unchanged (at 43%) when focusing on participants with advanced adenoma in the distal colon and rectum only. Subsite-specific per-advanced-adenoma sensitivity strongly varied from 5% for advanced adenomas located in the cecum to 44% for advanced adenomas (and >50% for large advanced adenomas) located in the descending or sigmoid colon. Sensitivity for detecting nonadvanced adenomas was very low regardless of their location, with per-adenoma sensitivities essentially equal to false positive rates in neoplasm-free participants. Our results may partly explain the variation in site specific sensitivities reported in previous studies. Whereas some of these studies had reported apparent sensitivities, 14 others reported true sensitivities 5, 6, 8, 9, 12, 13 according to our terminology. To our knowledge, our study is the first to comprehensively report and compare both sensitivity measures.
In accordance with our results, all previous estimates of true sensitivity for proximal advanced adenomas were lower than the corresponding estimates of true sensitivity for distal advanced adenomas, except for one small study from South Korea including 33 participants with proximal advanced adenomas only. 8 Our estimate of true sensitivity for proximal advanced adenoma (14%) is furthermore very close to the corresponding estimate reported from the study so far including the highest number of participants with proximal advanced precancerous lesions. 13 The joint look at true and apparent sensitivities in our study suggests that FIT positivity in the presence of proximal advanced adenomas may in many cases result from co-occurrence of advanced adenoma in the distal colon and rectum, for which sensitivity seems to be much higher than sensitivity for proximal advanced adenomas.
To our knowledge, this is the first study reporting detailed subsite specific per-adenoma sensitivities of advanced adenomas. Our results indicate a very strong gradient of sensitivities for advanced adenomas located in the colon, ranging from 4% for advanced adenomas in the cecum to 44% for advanced adenomas (>50% for large advanced adenomas) in the descending and sigmoid colon, and slightly lower levels for rectal advanced adenomas. Our results thereby strongly expand current evidence which mainly focused on overall sensitivity of FIT performance which was found to be between 20 and 30% in the majority of studies. 21 Although there is room for improvement, these overall levels of sensitivity are substantially higher than those of guaiac based fecal occult blood tests and suggest that FIT based screening has potential to reduce CRC incidence in addition to reducing CRC mortality. 21 Although the reasons for strong gradient in site specific sensitivity in the colon cannot be directly inferred from our data, there are a number of plausible reasons that may explain the observed patterns. First, colonic transition time, and hence the potential for degradation is longer for hemoglobin resulting from proximal than from distal lesions. Although data on intracolonic hemoglobin degradation are sparse, there is evidence on substantial hemoglobin degradation after stool collection even at temperatures typically much lower than 378C. 22, 23 Second, distal adenomas are more often pedunculated, and this shape of adenomas seems to be more prone to bleeding than flat and sessile adenomas which are more often found in the proximal colon. 24 Third, the typically harder consistency of stool may more easily induce bleeding when passing through the distal colon and rectum. Although the observed gradient of site specific sensitivities within the colon seems to be consistent with these potential mechanisms, the somewhat lower sensitivity for advanced adenomas in the rectum than in the descending and sigmoid colon appears to be surprising on first view. A potential explanation might be a selection affect, as people with rectal advanced adenomas might more often undergo diagnostic colonoscopy due to visible bleeding or a positive FOBT and might therefore be underrepresented among (typically asymptomatic) participants of screening colonoscopy who were included in our study.
Our findings of high sensitivity for detecting both proximal and distal CRC, along with major variation in site specific sensitivity of FIT for detecting advanced adenomas may have important implications for FIT-based screening. On one hand, FIT-based CRC screening would be expected to strongly reduce mortality from both proximal and distal CRC (by reliably detecting both proximal and distal preclinical cancer). On the other hand, expected long-term reduction of incidence (by detecting and removing advanced adenomas) would be expected to be much stronger for distal than for proximal CRC.
Even with screening colonoscopy, which is assumed to have close to 90% sensitivity for detecting advanced adenomas and to also detect the vast majority of nonadvanced adenomas in the entire colon and rectum, 25 prevention seems to be less effective with respect to proximal compared to distal CRC. 26 With substantially lower sensitivity for proximal compared to distal advanced adenomas, the gradient in effectiveness of prevention according to CRC site would be expected to be even larger for FIT-based screening, a feature shared with FS-based screening. [27] [28] [29] [30] The higher sensitivity for detecting distal advanced adenomas appears particularly advantageous and clinically relevant though, because the majority of advanced adenomas and CRC occur in the distal colon and rectum and the screening colonoscopy results suggest that detection and removal of adenomas is particularly effective in the distal colon and rectum.
Our findings may also have important implications for combined use of FIT and sigmoidoscopy which has been suggested as a promising option for CRC screening. 31, 32 A major rationale for adding FIT to flexible sigmoidoscopy (FS) based screening would be to increase the yield of proximal neoplasms missed by FS. Our results suggest, however, that this incremental yield may be more limited than hoped for, at least under the common practice of conducting colonoscopy in case of finding relevant neoplasms in the distal colon and rectum at FS anyway. In this situation, sensitivity for detecting additional adenomas exclusively occurring in the proximal colon appears to be very low. Further research should address whether lowering the cutoff for FIT positivity might be a reasonable option to increase sensitivity for enhanced detection of proximal neoplasms in such screening strategies. Irrespective of potential adaption of the cutoff, the high sensitivity for detecting proximal CRC 5, 8, 13 may still make additional FIT testing worthwhile with respect to CRC early detection and reducing CRC mortality.
Our results were obtained among users of screening colonoscopy in Germany in whom relatively high prevalences of CRC and advanced adenomas were observed. Somewhat lower prevalences were observed or would be expected in other countries, such as the United States, either due to higher prevalences of any previous sigmoidoscopy or colonoscopy with removal of colorectal neoplasms, or due to lower occurrence of colorectal neoplasms. Such differences should though not have a major impact on subsite-specific variation in FIT sensitivity. Our results suggest, however, that overall sensitivity of FIT for detecting advanced adenomas may vary according to the relative frequency of proximal and distal advanced adenomas which may vary between populations.
Our results furthermore focused on a single application of a FIT. In FIT based screening programs with repeated application of FIT (e.g., in intervals of 1-3 years) lower prevalences of advanced neoplasms are to be expected in subsequent screening rounds due to prior detection and removal of advanced neoplasms. This should primarily affect the positive predictive value but not necessarily the sensitivity of FITs which our study focused on.
Strengths of our study include the large sample size, conduction in a true screening setting, and availability of screening colonoscopy results in all participants which enabled the most detailed analysis of subsite specific sensitivities available to date. Nevertheless, despite the large overall sample size, numbers of some of the outcomes, in particular CRC or subsite-specific advanced adenomas, were still rather limited leading to rather wide confidence intervals for several of the sensitivity estimates. Sample size limitations also hindered analyses for specific subgroups of major interest, such as subgroups defined by sex, which should be addressed in further, even larger studies.
Despite these limitations, our study shows that true sensitivity of FITs for detecting advanced adenomas strongly varies by adenoma site, with much higher sensitivity for distal than for proximal advanced adenomas. Positive FIT results in the presence of proximal advanced adenomas may often result from accompanying distal advanced adenomas for which sensitivity seems to be much higher. Our results suggest that FIT-based screening will strongly reduce both proximal and distal CRC mortality (by reliably detecting both proximal and distal preclinical cancer), but have a substantially stronger effect on preventing distal compared to proximal CRC, with the gradient in effectiveness being expected to be even larger than for colonoscopy-based screening. The recently proposed multitarget stool DNA test which combines DNA testing with a FIT component showed some promising increase in the detection of proximal neoplasms compared to FIT alone, albeit at some loss in specificity 13 and substantially higher costs. Further efforts are required to develop noninvasive tests for cost-effective CRC screening with enhanced detection of cancer precursors in the proximal colon and enhanced potential of preventing proximal CRC, while maintaining or even increasing the high specificity and the remarkable sensitivity for distal advanced adenomas already achieved with FITs.
